Chemours has completed its planned procedures with respect to an internal review that it first announced on 29 February. This essentially confirmed the details revealed in an interim report on 7 March. More will be published in the compensation discussion and analysis in the proxy statement for the 2024 annual meeting.

The Audit Committee of the Chemours board has delivered a “substantially complete” report of the findings of the internal review it was tasked to complete with regard to the conduct of CEO Mark Newman, CFO Jonathan Lock and principal accounting officer Camela Wisel. All three were put on administrative leave on 29 February pending its completion.